HURA(HURA)
HURA
11/22/26
TuHURA Biosciences (HURA)
Sunday
1:57 AM ET
ThesisTuHURA Biosciences: the story is balanced — Clinical trial data releases - particularly efficacy signals (ORR, PFS) and safety profiles from ongoing Phase 1/2…
Revenue Outlook
What Moves the Stock
- 01Clinical trial data releases - particularly efficacy signals (ORR, PFS) and safety profiles from ongoing Phase 1/2 studies
- 02Cash position updates and financing announcements - dilutive equity raises, PIPE transactions, or strategic partnerships
- 03FDA regulatory interactions - IND clearances for new programs, Fast Track or Orphan Drug designations
- 04Pipeline advancement milestones - patient enrollment completion, dose escalation decisions, expansion cohort initiations
- 05Competitive landscape shifts - rival programs showing superior efficacy or safety in similar indications
- 06No current revenue - pre-commercial clinical-stage company
- 07Future potential: licensing agreements or partnerships for pipeline assets
- 08Future potential: product sales upon regulatory approval (2028+ earliest scenario)
FY2025 Snapshot
- Revenue
- $0.00
- Gross Margin
- 0.0%
- Op. Margin
- 0.0%
- Net Margin
- 0.0%
- Net Income
- $-30M
- NI Growth
- -38.6%
- EPS
- $-0.63
- 1Y Return
- -28.6%
HURA Chart
My Notes
- momentum/speculative - This is a binary-outcome, high-risk/high-reward clinical-stage play attracting biotech specialists…
- Rising rates create significant headwinds through multiple channels: (1) higher discount rates compress NPV of distant future cash flows…
- Watch on earnings: Monthly cash burn rate and ending cash balance - determines survival timeline, Clinical trial patient enrollment numbers and protocol amendments, Nasdaq minimum bid price compliance - stock below $1 risks delisting, further limiting financing options.
One Sentence Summary:
TuHURA Biosciences: the story is balanced — clinical trial data releases - particularly efficacy signals (orr, pfs) and safety profiles from ongoing phase 1/2 studies.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
HURA Financial Metrics
Explore 130+ historical metrics & ratios
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance